TriSalus Life Sciences, Inc. (TLSI) financial statements and ratios from SEC XBRL: revenue $45.15M (TTM), net margin -86.9%, revenue growth 53.4% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $45.15M |
| Net Margin | -86.9% |
| Revenue Growth (YoY) | 53.4% |
| EPS Growth (YoY) | 40.5% |
| FCF Growth (YoY) | -54.0% |
| Price / Book | 25.18 |
| Price / Sales | 7.89 |
| FCF Yield | -12.6% |
| Altman Z-Score | -10.84 (distress) |
| Piotroski F-Score | 4/9 |
| Sector P/E (Healthcare) | 21.6 |
TLSI overview · TLSI earnings · TLSI KPIs · TLSI investor relations · TLSI ownership · TLSI peers · TLSI filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.